Display options
Cite
Takasaki H, Yamamoto W, Ishii Y, et al. Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass. Indian J Hematol Blood Transfus. 2014;31(3):346-51doi: 10.1007/s12288-014-0479-9.
Takasaki, H., Yamamoto, W., Ishii, Y., Takahashi, H., Watanabe, R., Harada, T., Kawasaki, R., Hashimoto, C., Motomura, S., Tomita, N., Ishigatsubo, Y., & Sakai, R. (2015). Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 31(3), 346-51. https://doi.org/10.1007/s12288-014-0479-9
Takasaki, Hirotaka, et al. "Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass." Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion vol. 31,3 (2015): 346-51. doi: https://doi.org/10.1007/s12288-014-0479-9
Takasaki H, Yamamoto W, Ishii Y, Takahashi H, Watanabe R, Harada T, Kawasaki R, Hashimoto C, Motomura S, Tomita N, Ishigatsubo Y, Sakai R. Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass. Indian J Hematol Blood Transfus. 2015 Sep;31(3):346-51. doi: 10.1007/s12288-014-0479-9. Epub 2014 Dec 03. PMID: 26085719; PMCID: PMC4465504.
Copy Download .nbib Format: NLM
Share it on

Indian J Hematol Blood Transfus. 2015 Sep;31(3):346-51. doi: 10.1007/s12288-014-0479-9. Epub 2014 Dec 03.

Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Hirotaka Takasaki, Wataru Yamamoto, Yoshimi Ishii, Hiroyuki Takahashi, Reina Watanabe, Taishi Harada, Rika Kawasaki, Chizuko Hashimoto, Shigeki Motomura, Naoto Tomita, Yoshiaki Ishigatsubo, Rika Sakai

Affiliations

  1. Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515 Japan.
  2. Department of Internal Medicine and Clinical Immunology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.

PMID: 26085719 PMCID: PMC4465504 DOI: 10.1007/s12288-014-0479-9

Abstract

We retrospectively analyzed the prognosis of patients with diffuse large B cell lymphoma (DLBCL) and a bulky mass at diagnosis. We retrospectively analyzed clinical data for 29 consecutive DLBCL patients with an initial bulky mass receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy from 2004 to 2011. Bulky disease was defined as a measurable tumor mass >10 cm in diameter or a mediastinal mass >1/3 of the chest diameter. Patients with primary mediastinal large B-cell lymphoma were excluded. The median age was 65 years (20-78 years) and the maximum tumor diameter was 11.5 cm (10.0-17.0 cm). Complete response and partial response were achieved in 14 patients each, while 1 patient had progressive disease. The 3-year overall survival (OS) rate and progression-free survival (PFS) rate were 66 and 56 %, respectively. Findings on post-treatment positron emission tomography-computed tomography (PET-CT) were significantly associated with OS (34 % for patients with abnormal uptake vs. 75 % for those without, P = 0.014), and were also associated with PFS (36 vs. 83 %, respectively, P < 0.001). Nine patients with a single site of abnormal uptake on PET-CT underwent radiotherapy and 5 of them subsequently relapsed. An initial bulky mass does not indicate a poor prognosis of DLBCL. However, the post-treatment PET-CT findings may have predictive value in DLBCL patients with a bulky mass.

Keywords: Bulky mass; Diffuse large B-cell lymphoma; PET–CT

References

  1. Lancet Oncol. 2008 May;9(5):435-44 - PubMed
  2. J Clin Oncol. 2005 Jul 20;23 (21):4652-61 - PubMed
  3. J Clin Oncol. 2007 Feb 10;25(5):579-86 - PubMed
  4. Am J Med. 1977 Aug;63(2):177-82 - PubMed
  5. J Clin Oncol. 1989 Nov;7(11):1630-6 - PubMed
  6. Cancer Res. 1986 Oct;46(10):5372-9 - PubMed
  7. Eur J Haematol. 2011 Nov;87(5):434-40 - PubMed
  8. Ann Intern Med. 1986 Jun;104(6):757-65 - PubMed
  9. Ann Oncol. 2006 Jan;17(1):123-30 - PubMed
  10. J Clin Oncol. 2006 Jul 1;24(19):3121-7 - PubMed
  11. Int J Hematol. 2012 Aug;96(2):241-6 - PubMed
  12. Ann Hematol. 2010 Oct;89(10):985-91 - PubMed
  13. Leuk Lymphoma. 2014 Jan;55(1):31-7 - PubMed
  14. N Engl J Med. 2002 Jan 24;346(4):235-42 - PubMed
  15. J Clin Oncol. 1991 Feb;9(2):220-6 - PubMed
  16. Int J Lab Hematol. 2008 Feb;30(1):53-7 - PubMed

Publication Types